Seven patients in the LCK group discontinued diabetes medications: 5 (31%) discontinued a sulfonylurea (glyburide or glipizide), 2 (13%) discontinued a dipeptidyl peptidase −4 inhibitor (sitagliptin), and 2 (13%) discontinued metformin; some participants discontinued more than one class of diabetes medication. This evidence concerns the gene DPP4 and diabetes mellitus.